Kornimate/medical-research-clean huggingface dataset:
melanocortin gene expression in lymphocytes of polymyalgia patients

Conditions: Polymyalgia Rheumatica

Summary: polymyalgia rheumatica (pmr) is a systemic inflammatory disorder with unknown etiology and overlapping symptoms with giant cell arthritis and rheumatoid arthritis (ra). the proteomic profile of pmr patients remains uncharacterized and biomarker studies very limited. the primary aim of this study was to thoroughly investigate the lymphocyte expression of melanocortin receptors, and the serum proteome during glucocorticoid treatment of pmr with a focus on acute-phase reactions, the complement system, and pro-inflammatory cytokines.

polymyalgia rheumatica (pmr) is a prototypic systemic inflammatory disease with overlapping symptoms similar to late onset rheumatoid arthritis (ra), giant cell arthritis (gca), and cancer \[1\]. the etiology of pmr remains largely unknown, but it has been suggested that an age-related decline in the adaptive immune system might play a role in an over-compensatory inflammatory innate immune response \[2\]. some genes and polymorphisms involved in initiation and regulation of inflammation have been associated with pmr \[3,4\] and polymorphisms are more predominant in the northern european than mediterranean population \[5\]. pmr has been somewhat successfully treated with glucocorticoids (e.g. prednisone) for more than half a century \[6\]. due to the lack of causative molecular knowledge about the driving factors of inflammatory activation, and lack of treatment alternatives, glucocorticoids are still applied as the first line treatment today \[7\]. relapses are common during standard glucocorticoid treatment \[8\], and randomized trials have failed to provide new treatment options \[9,10\]. however, recent progress in gca treatment \[11\] have paved the way for biological treatment of pmr. only few serological biomarkers have been associated to pmr pathogenesis and disease activity while the pathogenesis of ra has been more thoroughly investigated. hence, there is an unmet need to elucidate the pathophysiology of pmr. in this pilot-study, we therefore explored the potential to identify new serological markers at disease onset, which could be responsive to glucocorticoid treatment, which could be linked to pmr pathology. we did this using state-of-the-art quantitative proteomics profiling to investigate serum proteins from pmr patients before and after treatment with glucocorticoids for three months. in addition, we compared these patients with dmard naïve ra patients, and healthy controls for potential molecular similarities. hence, we applied advanced, qpcr to investigate lymphocyte expression, and mass spectrometry (ms) to measure serum proteins, and compared the results with serum cytokines.

Eligibility criteria:
inclusion criteria: * the pmr diagnosis fulfilled the acr 1987 criteria \[20\]. additional inclusion criteria were elevated crp, and sedimentation rate, ultrasound verified synovitis \[21\], and \]. exclusion criteria: * no cancer related findings on computed tomography (ct) of the abdomen, and chest x-ray to increase specificity as described by acr 2012 classification criteria \[22
impact of an improved rehabilitation program after a scheduled hysterectomy.

Conditions: Post-Op Complication

Summary: it is an observational study, prospective in order to assess the impact of the implementation of an early rehabilitation program on post-operative recovery. this is measured by the qor15 questionnaire in patients operated on for a programmed hysterectomy, it takes place in the gynecology department of the chr metz-thionville hospital.

this program implemented will comply with has recommendations. the only change in management for patients participating in the study is the completion of the self-questionnaire qor-15 on d-1 (the day before surgery), d0 (the day of the surgery) and d1 (the day after the surgery). it is planned to include 74 patients before the implementation of the early rehabilitation protocol and 74 patients after the implementation of the early rehabilitation protocol. the total duration of inclusion is established at 18 months. the measures applied should improve the patient's well-being and accelerate his return to normal life and therefore reduce the length of his stay.

Eligibility criteria:
inclusion criteria: * indication of a scheduled hysterectomy * presence of a utero-ovarian affection, deemed resectable and requiring a regulated hysterectomy (outside the context of the emergency) associated or not with pelvic or lumbar-aortic dissection. * classified asa 1 to 3 * informed about the principles of improved rehabilitation by the surgeon and the anesthesiologist + written document (accessible on the site www.grace-asso.fr). * able to return home after discharge from the hospital, having a telephone and being able to contact their doctor or the service if necessary or transferred to a convalescent home at their request. exclusion criteria: * patients included in another study * refusal to use data by the patient * inability to respond to self-questionnaires due to cognitive impairment, difficulties in reading or understanding the french language * patients included in another study * patients with severe or unbalanced associated conditions

Keywords: hysterectomy post operative
a study of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in women with folate receptor (fr) alpha positive advanced epithelial ovarian cancer (eoc), primary peritoneal or fallopian tube cancer

Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Ovarian Cancer

Summary: this is a phase 3, open label, randomized study designed to compare the safety and efficacy of mirvetuximab soravtansine to that of selected single-agent chemotherapy (investigator's choice) in women with platinum-resistant fr-alpha positive advanced eoc, primary peritoneal cancer and/or fallopian tube cancer.

participants will be randomized to either mirvetuximab soravtansine or investigator's choice chemotherapy.

Eligibility criteria:
inclusion criteria: * participants must be diagnosed with advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer * participants must have folate receptor alpha positive tumor expression as defined in the protocol * participants must have platinum-resistant ovarian cancer, defined as progression within 6 months from completion of a minimum of four cycles of platinum-containing therapy. * participants must have received at least one but no more than three prior systemic treatment regimens and for whom single-agent chemotherapy is appropriate as the next line of treatment * participants must have at least one lesion that meets the definition of measurable disease by recist 1.1 exclusion criteria: * diagnosis of clear cell, low grade ovarian cancer or mixed tumors * participants with primary platinum-refractory disease * serious concurrent illness or clinically relevant active infection as defined in the protocol * prior treatment with mirvetuximab soravtansine * women who are pregnant or breast feeding

Keywords: epithelial ovarian cancer fallopian tube cancer primary peritoneal cancer imgn853 adc antibody drug conjugate immunogen antibody folate receptor alpha mirvetuximab soravtansine phase 3 platinum-resistant mirv
the role of adjuvant corneal crosslinking in the management of infective keratitis

Conditions: Infective Keratitis

Summary: this was a prospective, single centre, randomised controlled study to evaluate the clinical effectiveness of corneal collagen crosslinking as an adjuvant to antimicrobial therapy.

this randomised controlled study of forty eyes of forty patients was conducted to assess the impact of corneal collagen crosslinking in addition to antimicrobial therapy. all forty patients presenting with infective keratitis of various aetiologies (bacterial, fungal, acanthamoeba) were screened and then randomly allocated equally to two groups (a and b). group a patients were to be offered standard targeted anti-microbial therapy whilst group b were offered cxl in addition to the standard targeted anti-microbial therapy. patients were evaluated clinically for visual acuity; infection parameters and dimensions were measured on slit lamp and optical coherence tomography. evaluations were noted at the baseline visit and subsequently on days 7, 14, and day 30 of treatment

Eligibility criteria:
inclusion criteria: • patients presenting with infectious keratitis exclusion criteria: * infective keratitis \< 1mm from limbus * corneal thickness \< 350μm * previous herpetic eye disease * expectant and nursing women
dpbrn reasons for replacement or repair of dental restorations

Conditions: Dental Caries

Summary: the purpose of this study was to document the reasons for replacement or repair of defective restorations ("fillings") and to record the restorative material of the failed restoration and the material used in the replacement restoration on permanent ("adult") teeth.

the aims of this study were to (1) quantify the prevalence of reason(s) for replacing existing restorations in dpbrn practices; (2) quantify the percentages and types of restorative materials of failed restorations that are being replaced in dpbrn practices; (3) quantify the percentages and types of restorative materials used to replace or repair failed restorations in dpbrn practices; and (4) test the hypothesis that dpbrn practitioner-investigators who reported in a previous study that they treat enamel lesions operatively are more likely in actual patients as in this study to replace entire restorations rather than do repairs and are more likely to report the clinical diagnosis of secondary caries as a reason for replacement.

Eligibility criteria:
inclusion criteria: * participants directly involved in this study were patients who sought dental treatment in the practitioner-investigators practices * any tooth surface that was previously restored was eligible for this study, provided that it was on a permanent ("adult") tooth. this means that permanent first molars were eligible, which typically erupt at about age 6 years. this means that persons age 6 and older were enrolled in the study and there was no upper age limit.

Keywords: dental caries assessments dental materials
assessing strategies for increasing male involvement in malawi's antenatal program

Conditions: HIV

Summary: in sub-saharan africa, engaging men in hiv prevention, care, and treatment has proven challenging. along all steps of the hiv care-seeking cascade, men exhibit worse care-seeking behaviors than women. they are less likely to be tested for hiv, initiate combination antiretroviral therapy (cart), and be retained in cart care. additionally, men rarely engage in the care of their female sex partners, even though couple care-seeking is associated with marked improvements in condom use within hiv-discordant couples. option b+, malawi's program for providing immediate, lifelong combination antiretroviral therapy (cart) to all hiv-infected pregnant women at the time of diagnosis, is an important entry-point for involving male partners in care. this is a pilot randomized controlled trial (n=200 women) comparing two strategies of male partner involvement within the option b+ program. in both arms (patient referral and contract referral) women will be encouraged to invite their male partners to accompany them to the clinic for couple hiv counseling and testing. in the contract referral arm, if the couple does not present within one week, the male partner will receive a home visit encouraging them to present to the clinic. we will compare the two arms for 1) uptake of couple hiv counseling and testing (chct), 2) uptake of cart for women, and 3) linkage to care for hiv-infected men. results are expected to inform a larger trial and ultimately improve care-seeking in malawi's hiv program. objective 1: determine acceptability of male partner recruitment for chtc within an option b+ context. we will assess acceptability of eligible females to participate in this pilot rct and reasons for non-participation. objective 2: assess whether study arm (patient referral versus contract referral) is associated with chtc uptake. we will conduct a pilot randomized controlled trial (rct) of male partner recruitment. this study will contain two arms: patient referral and contract referral for uptake of chtc (primary outcome).


Eligibility criteria:
inclusion criteria: * 18 years old or 16-17 years old and married * pregnant * received a positive hiv-test within the last day * will be in lilongwe for the next month * able and willing to give locator information for \>1 male partner in the bwaila district hospital catchment area (either a mobile number, a physical address, or both) exclusion criteria: * enrolled/enrolling in the promise study * initially presenting with a male sex partner

Keywords: couple hiv testing and counseling disclosure discordant hiv malawi
comparing the efficacy of the convatec engenex® negative pressure wound therapy device to moist wound therapy

Conditions: Diabetes; Foot Wound

Summary: this is an investigator-initiated prospective, randomized, controlled study. hypothesis/objective: the study will evaluate the rates of wound healing among patients with lower extremity diabetic wounds comparing two groups of patients. group 1, the control group, will be treated with the standard of care treatment of moist wound therapy. group 2 will be treated with convatec engenex® npwt. both groups will be treated in the inpatient and outpatient setting. it is expected that the npwt device will be an effective therapy that expedites time to closure and demonstrates a significant decrease in the size and depth of the wound over the course of the 12 week therapy as compared to the standard of care.

after determining if you meet the criteria to be included in the study, your wound will be debrided (cleansed of any dead tissue or infection). you will then be randomly placed into one of two treatment groups. group 1 will be the control group and a moist wound therapy will be applied to the wound. either you or home nursing will then change the dressing twice a week. group 2 will have a negative pressure wound therapy (npwt) dressing applied. the npwt dressing will be changed twice a week by home nursing. you will return to clinic every 2 weeks for a total of 12 weeks for observation and assessment of the diabetic foot ulcer. if wound healing occurs prior to 12 weeks, a final assessment visit will be done and the status of the healed ulcer will be assessed.

Eligibility criteria:
inclusion criteria: 1. subject is 18 years of age or older 2. subjects with chronic lower extremity diabetic wounds, with or without a previous history of partial foot amputation. 3. subject has diabetes mellitus (type 1 or type 2) 4. university of texas classification 1a-3a or 1b-3b 5. ability and willingness to understand and comply with study procedures and to give written informed consent prior to enrollment in the study. exclusion criteria: 1. subjects \< 18 years of age 2. subject is non-diabetic 3. subjects who present with wounds of etiology other than diabetes 4. subject demonstrates increased signs of clinical infection 5. has active malignant disease of any kind. a subject, who has had a malignant disease in the past, was treated and is currently disease-free, may be considered for study entry. 6. university of texas classification 1c-3c 7. subjects participating in any other trials in regards to the diabetic foot ulcer.
the relationship between mdscs and nk cells activity of chc patient treated by daas

Conditions: Chronic Hepatitis C

Summary: hepatitis c virus (hcv) infection is easy to chronic and can progress to cirrhosis and liver cancer. direct-acting antiviral treatment can significantly improve the prognosis of the disease and the efficacy is seemingly not affected by a variety of viral factors. in addition, direct-acting antiviral agents therapy may affect the transformation of the immune cells and ameliorate the host immune status consequently. this study mainly investigated the relationship between direct acting antiviral treatment effect and the functional activity of myeloid-derived suppressor cells (mdscs) and natural killer cells (nk cells) in chronic hepatitis c.

32 treatment-naive chc patients and 20 healthy controls were recruited. patients were examined before daas therapy (0w) and at weeks 4 (4w) and weeks 12 (12w) and weeks24 (24w) of the therapy. the percent age of myeloid-derived suppressor cells and nk cells of the peripheral blood were analyzed by flow cytometry. the investigators discuss the relationship between direct acting antiviral treatment effect and myeloid-derived suppressor cells and nk cells activity in chronic hepatitis c.

Eligibility criteria:
inclusion criteria: * positive serum anti-hcv antibody or serum hcv-rna, chc patients without any treatment exclusion criteria: * patient has a history of clinical signs/symptoms of hepatic decompensation (child-pugh grade b or c) or ascites, esophageal variceal bleeding, hepatic encephalopathy, or spontaneous bacterial peritonitis. * patient has a history of hepatocellular carcinoma (hcc) or suspected symptoms of hcc, such as suspicious foci on imaging studies and/or serum alpha-fetoprotein (afp)\>50ng/ml. * patient has received ifn or other immunomodulatory treatment within 52 weeks before screening. patient has a medical condition that requires frequent use of systemic acyclovir or famciclovir. * patient has a medical condition that requires frequent use of systemic corticosteroids, however topical and inhaled corticosteroids are allowed. patient has used hepatotoxic drugs within one month. patient has overtaken alcohol (\>40g/day) or abused illicit drugs in recent one year. * pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test. * patients who co-infected with hav, hbv, hdv, hev,hiv(human immunodeficiency virus ) patient has one or more additional known primary or secondary causes of liver disease, other than hepatitis c (e.g., alcoholism, autoimmune hepatitis). history of malignancy of any organ system.

Keywords: chronic hepatitis c direct-acting antiviral agents myeloid-derived suppressor cells nk cells
delayed secondary reconstruction of alveolar clefts using autogenous symphyseal particulate bone versus iliac cancellous bone: a randomized clinical trial

Conditions: Bone Facial Bone

Summary: patients with alveolar clefts whose ages are after 12 years (after eruption of all permanent dentition) were recruited and treated either by particulate bone grafting from the symphysis or from the anterior iliac crest


Eligibility criteria:
inclusion criteria: * cleft alveolus patients of both genders after eruption of all permanent dentition exclusion criteria: * previous failed repairs of alveolar clefts and bone metabolic diseases
a randomized trial of endovascular treatment for acute posterior large vessel occlusion

Conditions: Vertebrobasilar Stroke

Summary: the aim of this trial is to investigate whether endovascular treatment can improve the 90-day functional outcome of acute large vessel occlusion in the posterior circulation.

at least seven randomized controlled trials have consistently shown that endovascular treatment can improve the functional outcome of stroke patients with acute anterior large vessel occlusion. however, these trials did not include patients with large vessel occlusion in the posterior circulation. the hypothesis of this trial: compared with standard medical treatment alone, standard medical treatment combined with endovascular treatment can significantly improve the 90-day functional outcome of acute large vessel occlusion in the posterior circulation.

Eligibility criteria:
inclusion criteria: 1. age: i. 18 \~ 80 years old, pc-aspects score ≥ 6; ii. \> 80 years old, pc-aspects score ≥ 8 and mrs = 0 before the onset 2. nihss score ≥ 10 before randomization; 3. va-v4 or basilar artery occlusion proved by cta/mra/dsa; 4. time from stroke onset to randomization within 23.5 hours; 5. written informed consent is obtained from patients and/or their legal representatives. exclusion criteria: 1. ct or mr evidence of intracranial hemorrhage; 2. pre-morbidity with a modified rankin scale score ≥ 3; 3. the patient is in deep coma; 4. currently in pregnant or lactating or serum beta hcg test is positive on admission; 5. arterial tortuosity and/or other arterial disease that would prevent the device from reaching the target vessel; 6. contraindication to radiographic contrast agents, nickel, titanium metals or their alloys; 7. significant mass effect in the cerebellar hemisphere or hydrocephalus on imaging; 8. imaging manifestations of diffuse bilateral brainstem ischemia; 9. multivessel occlusive disease (combined with anterior and posterior circulation occlusion or subtotal occlusion); 10. cerebral vasculitis, intracranial arteriovenous malformation, aneurysm, or brain tumor with mass effect; 11. participating in other clinical trials; 12. any terminal illness with life expectancy less than 6 months; 13. patients with a preexisting neurological or psychiatric disease that would confound the neurological functional evaluations; 14. past neurological or psychiatric diseases that hinder the assessment of neurological function; 15. unlikely to be available for 90-day follow-up.

Keywords: endovascular treatment thrombolysis
novel index (pimr) in pah

Conditions: Pulmonary Hypertension

Summary: the chief regulator of resistance in pulmonary arterial hypertension (pah) is the small arteries. in the heart, the invasive measurement of the resistance of the small arteries has been shownto be safe, easy, reliable, and prognostic. this study is intended to translate prior work in heart arteries to the pah space and invasively measure the resistance of the small arteries of the lung (pulmonary index of microcirculatory resistance \[pimr\]) and the coronary artery supplying the right ventricle (acute marginal of the rca; rv-imr). importantly, these measurements will be made during standard of care cardiac catheterizations (right heart catheterization \[rhc\] +/- left heart catheterization). the correlation between these new indices and the standard ones measured during rhc typically used to determine the severity of pulmonary hypertension will be analyzed. in addition, among newly diagnosed patients, the study will evaluate how these indices change 6 months after starting treatment. finally, the association of these indices with clinical outcomes at 1 year will be assessed. the findings from this study may deliver an immediate impact to patient care by identifying a new metric to help better identify those who may benefit from a more intensive, personalized treatment regimen.


Eligibility criteria:
inclusion criteria: * diagnosis of group 1 pah with invasive pulmonary hypertension defined as: mean pulmonary arterial pressure ≥ 20 mmhg, pulmonary capillary wedge pressure \< 15 mmhg, and pulmonary vascular resistance ≥ 3 wood units. * serum creatinine \< 2.0 mg/dl * able to provide informed written consent exclusion criteria: * other groups/forms of pulmonary hypertension (i.e. groups 2-5) * contraindicated to undergo fluoroscopy and/or coronary angiography * pregnancy

Keywords: pulmonary hypertension pulmonary index of microcirculatory resistance pulmonary arterial hypertension index of microcirculatory resistance